Takeda Pharmaceutical said labeling for Dexilant, or dexlansoprazole, was updated to say that the proton pump inhibitor is compatible with anti-coagulant Plavix, or clopidogrel. Previous research suggested that PPIs disrupt the anti-clotting effect of Plavix, by Sanofi and Bristol-Myers Squibb. Takeda consulted with the FDA regarding the label change.

Related Summaries